Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep;30(9):5597-5609.
doi: 10.1245/s10434-023-13757-0. Epub 2023 Jun 26.

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer

Julia H Gelissen  1 , Naomi N Adjei  2 , Blair McNamara  3 , Levent Mutlu  3 , Justin A Harold  3 , Mitchell Clark  3 , Gary Altwerger  3 , Peter R Dottino  3 , Gloria S Huang  3 , Alessandro D Santin  3 , Masoud Azodi  3 , Elena Ratner  3 , Peter E Schwartz  3 , Vaagn Andikyan  3
Affiliations
Review

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer

Julia H Gelissen et al. Ann Surg Oncol. 2023 Sep.

Abstract

Hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment modality that aims to target the main site of tumor dissemination in ovarian cancer, the peritoneum, by combining the benefits of intraperitoneal chemotherapy with the synergistic effects of hyperthermia all during a single administration at the time of cytoreductive surgery. High-quality evidence currently only supports the use of HIPEC with cisplatin at the time of interval cytoreduction after neoadjuvant chemotherapy for stage III epithelial ovarian cancer. Many questions remain, including HIPEC's role at other timepoints in ovarian cancer treatment, who are optimal candidates, and specifics of HIPEC protocols. This article reviews the history of normothermic and hyperthermic intraperitoneal chemotherapy in ovarian cancer and evidence regarding HIPEC implementation and patient outcomes. Additionally, this review explores details of HIPEC technique and perioperative care, cost considerations, complication and quality of life data, disparities in HIPEC use, and unresolved issues.

PubMed Disclaimer

References

    1. Cancer Stat Facts: Ovarian Cancer: National Cancer Institiute. Surveillance, Epidemiology, and End Results Program. Available at: https://seer.cancer.gov/statfacts/html/ovary.html .
    1. Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, Morice P, Pignata S, Ray-Coquard I, Vergote I, Baert T, Belaroussi I, Dashora A, Olbrecht S, Planchamp F, Querleu D. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. 2019;30(5):672–705. https://doi.org/10.1093/annonc/mdz062 . (Epub 2019/05/03). - DOI - PubMed
    1. Armstrong DK AR, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuk A, Chen LM, Chitiyo V, Cristea M, Derosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Gisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA, Leiserowitz G, Liu J, Martin L, Matei D, McHale M, McLean K, Miller DS, Percac-Lima S, Remmenga SW, Robertson S, Rodabaugh K, Schorge J, Stewart D, Thaker PH, Vargas R, Wahner Hendrickson A, Werner TL, Zsiros E. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 5.2022.
    1. Jones RB, Myers CE, Guarino AM, Dedrick RL, Hubbard SM, DeVita VT. High-volume intraperitoneal chemotherapy (“belly bath”) for ovarian cancer. Pharmacologic basis and early results. Cancer Chemother Pharmacol. 1978;1(3):161–6. https://doi.org/10.1007/bf00253116 . (Epub 1978/01/01). - DOI - PubMed
    1. Los G, Mutsaers PH, van der Vijgh WJ, Baldew GS, de Graaf PW, McVie JG. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res. 1989;49(12):3380–4 (Epub 1989/06/15). - PubMed

MeSH terms

LinkOut - more resources